最新ニュース CureVac (NASDAQ:CVAC) 株価情報

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV

Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) slipped 0.6% in Wednesday&#8217;s after-hours session following a volatile trading day. The decline came as new employment data pointed to a <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42873182/us-private-businesses-add-122000-jobs-in-december-the-labor-market-downshifted-to-a-more-modest-pace-of-growth">cooling U.S. labor market</a>, sparking concerns about a potential drop in retail trading activity and waning investor engagement on the platform.
What To Know: The ADP National Employment Report showed private employers added just 122,000 jobs in December, missing expectations and highlighting a slowdown in key sectors like manufacturing and trade.
Robinhood's business model relies heavily on retail trading volumes, which are sensitive to economic conditions affecting individual investors. 
A weakening labor market, coupled with slowing wage growth, reduces disposable income and dampens investor confidence — key drivers of trading activity on the platform. This can lead to lower revenue from payment for order flow, which represents a substantial portion of Robinhood's income.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42881085/is-labor-market-cooling-or-raising-fed-concerns-what-to-watch-in-fridays-jobs-report">Is Labor Market Cooling Or Raising Fed Concerns? What To Watch In Friday&#8217;s Jobs Report</a>
Additionally, decelerating wage gains could limit the influx of new retail investors, particularly younger users who form a significant portion of Robinhood's customer base. With fewer opportunities for speculative trading and reduced enthusiasm for high-risk assets, the platform may face declining engagement.
The broader economic uncertainty, including <a href="https://www.benzinga.com/news/25/01/42884213/dollar-hits-14-month-high-30-year-yields-near-critical-threshold-as-trump-reportedly-mulls-economic">elevated Treasury yields</a> and Federal Reserve tightening, compounds these risks, potentially eroding Robinhood's revenue streams tied to options and cryptocurrency trading, two of its most lucrative segments.
<h2 class="wp-block-heading">How To Buy Robinhood Stock</h2>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange-traded fund (ETF) that holds the stock itself or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Robinhood Markets&#8217; case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Robinhood has a 52-week high of $43.83 and a 52-week low of $10.38.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42899953/five-dead-in-los-angeles-wildfires-utilities-face-scrutiny">5 Dead, Nearly 180,000 Evacuated In Los Angeles Wildfires: California Utilities Face Scrutiny</a></li>
</ul>
Image: Shutterstock

News

HOOD

What's Going On With Robinhood Markets Stock?

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) on Thursday said it has successfully completed the Preliminary Design Review (PDR) for the Space Development Agency&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42895046/rocket-lab-on-track-to-advance-u-s-defense-capabilities-passing-major-milestone-in-development-of-" rel="noreferrer noopener">Tranche 2 Transport Layer-Beta (T2TL-Beta) program.</a>
This development marks a crucial step in Rocket Lab&#8217;s role as the prime contractor for the $515 million contract awarded in early 2024.
The contract involves the design, integration, testing, and commissioning of 18 advanced data transport satellites for the U.S. Department of Defense&#8217;s Proliferated Warfighter Space Architecture.
The PDR marks a significant step towards the detailed design phase, ensuring that Rocket Lab&#8217;s satellite design meets the mission&#8217;s rigorous requirements.
This comprehensive review covered mission architecture, vehicle space design, launch operations, and integration plans.
Read More:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected" rel="noreferrer noopener">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a>
The satellites are crucial for the PWSA, a low-Earth orbit constellation designed to provide secure, low-latency communications and missile tracking for U.S. defense.
Brad Clevenger, Rocket Lab&#8217;s President and CEO of National Security, emphasized that the milestone demonstrates the company&#8217;s commitment to delivering world-class satellite solutions.
The satellites will feature Rocket Lab&#8217;s vertically integrated subsystems, providing control over costs, schedules, and quality.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, RKLB stock has gained over 402% in the past year. Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).
Price Action: RKLB shares closed at $27.36 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally" target="_blank" rel="noreferrer noopener">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally </a></li>
</ul>

Equities

Markets

General

ARKX

RKLB

Rocket Lab Advances $515 Million Satellite Contract With Key Design Milestone: Details

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) has seen its stock drop 21% to $25.73 over the past month, driven by <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42599094/hims-hers-health-are-falling-today-whats-going-on">regulatory updates</a> from the FDA regarding tirzepatide injection shortages. However, the stock remains up over 200% over the past year, reflecting strong earnings performance.
What To Know: The company reported impressive <a href="https://www.benzinga.com/news/earnings/24/11/41728465/hims-hers-health-reports-better-than-expected-q3-results-details">third-quarter results</a> in November, with earnings of 32 cents per share, far exceeding analyst expectations of 4 cents. Revenue rose 77% year-over-year to $401.6 million, beating estimates of $382.2 million.
Subscriber growth surged 44%, reaching 2 million, and net income soared to $75.6 million, compared to a net loss of $7.6 million last year. However, gross margins narrowed slightly to 79%, down from 83% a year ago.
CEO Andrew Dudum highlighted the company's continued momentum, noting its focus on delivering accessible, personalized care. Hims &amp; Hers raised its fiscal 2024 revenue outlook to $1.46-$1.465 billion, indicating confidence in sustained growth.
Investor sentiment has otherwise been tempered over the past month by the FDA&#8217;s resolution of the tirzepatide shortage, which may pressure demand for compounded alternatives. Despite this, ongoing shortages of other GLP-1 drugs and strong fundamentals could position Hims &amp; Hers for potential long-term success.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42896114/us-2025-recession-odds-plummet-good-news-or-warning-sign">US 2025 Recession Odds Plummet: Good News Or Warning Sign?</a>
<h2 class="wp-block-heading">How To Buy HIMS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange-traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Hims &amp; Hers Health&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Hims &amp; Hers has a 52-week high of $35.02 and a 52-week low of $8.14.
It closed Wednesday down more than 7% at $25.73. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42899953/five-dead-in-los-angeles-wildfires-utilities-face-scrutiny">5 Dead, Nearly 180,000 Evacuated In Los Angeles Wildfires: California Utilities Face Scrutiny</a></li>
</ul>
Image: Shutterstock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Hims & Hers Health Stock?

Looking into the current session, CECO Environmental Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) shares are trading at $31.77, after a 1.21% decrease. Over the past month, the stock fell by 2.90%, but over the past year, it actually spiked by 66.60%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1736446510_0.png" alt="Past Year Chart" />

<h3>Comparing CECO Environmental P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
CECO Environmental has a lower P/E than the aggregate P/E of 101.05 of the Commercial Services &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736446510_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

CECO

Price Over Earnings Overview: CECO Environmental

A new report shows diverging sentiment across the biggest cryptocurrencies, despite <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42899397/ethereum-price-drops-5-in-7-days-truly-an-excellent-buy-the-dip-opportunity">market-wide downturn fears.</a>
Santiment, an on-chain analytics platform <a href="https://x.com/santimentfeed/status/1877132356496015364">analyzed</a> the top cryptocurrencies&#8217; based on social media trends over the past three months.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Past 7-Day Gains</td>
<td>Crowd Sentiment</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td> $93,820</td>
<td>-4.1%</td>
<td>3/5 (Neutral)</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td> $3,260</td>
<td>-5.6%</td>
<td>2/5 (Slightly Bearish)</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td> $187.7</td>
<td>-8.8%</td>
<td>4/5 (Semi Bullish)</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td> $2.3</td>
<td>-4.3%</td>
<td>4/5 (Slightly Bullish)</td>
</tr>
<tr>
<td>Binance Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>)</td>
<td> $686.60</td>
<td>-4.5%</td>
<td>3/5 (Neutral)</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td> $0.3211</td>
<td>-4.7%</td>
<td>1/5 (Bearish)</td>
</tr>
</tbody>
</table>
</figure>
Bitcoin: Crowd sentiment remains neutral following a Fed-induced price retrace on Dec. 20. Traders are waiting for a significant price move before committing to strong positions.
Ethereum: Momentum cooled after briefly reclaiming $4,000. Traders are cautious of a dip below $3,000, which could trigger panic selling and create buying opportunities.
XRP Ledger: XRP has outperformed peers with an 18% rally in early January, retaining bullish sentiment following its November-December surge.
Binance Coin: After a strong rally in November, BNB sentiment turned uncertain, particularly as it dropped below $700. Social media activity remains subdued unless significant price movements occur.
Solana: Despite a 25% decline over six weeks, Solana's community remains optimistic. Analysts suggest waiting for sentiment to fade further for better buying opportunities.
Dogecoin: Dogecoin has dropped 28% since its recent peak, experiencing minimal hype. Contrarian traders may see upside if broader markets turn bullish.
Statistics: Santiment noted that many wallets active in the last 30 days—including those holding BTC, ETH, Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), DOGE,and other altcoins—are operating at a loss. 
This suggests potential buying opportunities, as "blood in the streets" moments have historically led to profitable recoveries for seasoned traders.
While these signals point to a short- to mid-term recovery, they do not guarantee an immediate rebound.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f4ca; Average trading returns are a great representation of whether &#39;buying low&#39; or &#39;selling high&#39; is actually the right timing. Currently, wallets active in the past 30 days are in negative range for BTC, ETH, ADA, and DOGE, and the vast majority of altcoins. When MVRV&#39;s are… <a href="https://t.co/Y8yEahhIft">pic.twitter.com/Y8yEahhIft</a>
&mdash; Santiment (@santimentfeed) <a href="https://twitter.com/santimentfeed/status/1877075346450952204?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Diverging sentiment across major crypto assets underscores the importance of crowd psychology in market trends. 
Extreme bearish sentiment often marks entry points for contrarian traders, while excessive euphoria signals caution. 
Understanding these dynamics can help traders navigate volatile markets more effectively.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42724952/2025-outlook-bitcoin-to-150000-ethereum-to-5500-dogecoin-hits-1-galaxy-research-predicts">2025 Outlook: Bitcoin To $150,000, Ethereum To $5,500, Dogecoin Hits $1, Galaxy Research Predicts</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$DOGE

$ETH

$SOL

$XRP

Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish

"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success," said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences.
The Company reported cash and investments of approximately $183.8 million (unaudited) as of December 31, 2024.

IGMS

IGM Biosciences Halts Further Development Of Imvotamab And IGM-2644; Plans Reducing Its Workforce By 73%

BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) has been selected by India&#8217;s&nbsp;ONGC as a Technical Services Provider (<a target="_blank" href="https://ongcindia.com/web/eng/detail?assetEntry=69670160&amp;assetClassPK=69670154" rel="noreferrer noopener">TSP</a>) to enhance production from Mumbai High Field.
Notably, Shell and BP took part in the pre-bid process, with BP ultimately submitting the bid.
Under the agreement, BP is anticipated to receive a fixed fee for the initial two years, followed by a performance-based service fee linked to a share of net incremental production revenue, after recovering costs.
The contract duration is ten years and BP projects a significant increase in crude oil and gas production during the period, with crude output rising by ~44% from 45.47 MMT &#8211; 65.41 MMT baseline production and gas production growing by ~89% from 24.94 BCM &#8211; 47.22 BCM.
The company expects combined oil and gas output to rise by ~60%, from 70.40 MMToe &#8211; 112.63 MMToe.
The production boost is anticipated to be visible from FY26, with full-scale output targeted by FY28.
The incremental increase is expected to generate up to $10.3 billion in additional oil and gas revenue and up to $5 billion in incremental contributions to the Indian government through royalties, cess, and other levies.
Last month, BP and XRG&#8217;s new joint venture, Arcius Energy, will focus on building a <a target="_blank" href="https://www.benzinga.com/news/contracts/24/12/42513647/arcius-energy-takes-off-bp-and-xrgs-gas-power-play-in-egypt" rel="noreferrer noopener">competitive gas portfolio in Egypt</a>.
Investors can gain exposure to the stock via&nbsp;Texas Capital Funds Trust Texas Capital Texas Oil Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILT#NYSE">OILT</a>) and Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NDIV#NYSE">NDIV</a>)
Price Action: BP shares closed lower by 2.23% at $31.12 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42777105/russian-natural-gas-delivery-to-europe-halted-us-listed-lng-stocks-gain-as-exports-set-to-increase-in-2025" target="_blank" rel="noreferrer noopener">Russian Natural Gas Delivery To Europe Halted: US-Listed LNG Stocks Gain As Exports Set To Increase In 2025</a></li>
</ul>

Large Cap

Contracts

NDIV

OILT

BP Secures Landmark Deal With India's ONGC: Details

YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for YETI Holdings, presenting an average target of $42.0, a high estimate of $54.00, and a low estimate of $35.00. This current average represents a 7.35% decrease from the previous average price target of $45.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736445658_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of YETI Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Zatzkin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Noah Zatzkin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to YETI Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of YETI Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for YETI Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into YETI Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YETI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on YETI Holdings analyst ratings.</a>
<h2>Get to Know YETI Holdings Better</h2>
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
<h3>Breaking Down YETI Holdings's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining YETI Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: YETI Holdings's net margin excels beyond industry benchmarks, reaching 11.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.63%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): YETI Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.49%, the company showcases efficient use of assets and strong financial health.
Debt Management: YETI Holdings's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

YETI

What Analysts Are Saying About YETI Holdings Stock

10 analysts have expressed a variety of opinions on Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Varonis Systems, revealing an average target of $59.1, a high estimate of $70.00, and a low estimate of $47.00. Observing a 0.92% increase, the current average has risen from the previous average price target of $58.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1736445650_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Varonis Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Matt Dezort</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Varonis Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Varonis Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Varonis Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Varonis Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRNS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Varonis Systems analyst ratings.</a>
<h2>Unveiling the Story Behind Varonis Systems</h2>
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
<h3>Financial Insights: Varonis Systems</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Varonis Systems showcased positive performance, achieving a revenue growth rate of 21.06% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Varonis Systems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -12.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Varonis Systems's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.13%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Varonis Systems's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.4%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Varonis Systems's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.74, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRNS

Expert Outlook: Varonis Systems Through The Eyes Of 10 Analysts

In the latest quarter, 19 analysts provided ratings for SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $30.42, a high estimate of $34.00, and a low estimate of $25.00. This upward trend is apparent, with the current average reflecting a 4.9% increase from the previous average price target of $29.00.
<img src="https://www.benzinga.com/files/images/story/2025/1736445635_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of SentinelOne's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matt Dezort</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SentinelOne. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SentinelOne compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of SentinelOne's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of SentinelOne's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/S/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SentinelOne analyst ratings.</a>
<h2>All You Need to Know About SentinelOne</h2>
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
<h3>Breaking Down SentinelOne's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: SentinelOne displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 28.31%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: SentinelOne's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -37.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SentinelOne's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.79%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): SentinelOne's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: SentinelOne's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down SentinelOne: 19 Analysts Share Their Views

Ratings for Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) were provided by 37 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">10</td>
<td align="right">18</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $442.68, a high estimate of $538.00, and a low estimate of $330.00. Surpassing the previous average price target of $415.05, the current average has increased by 6.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1736445615_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ulta Beauty among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$445.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$480.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$538.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$457.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$475.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$370.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$425.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$394.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$480.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$490.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$450.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$410.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$510.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Sell</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$420.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$505.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$455.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$476.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$357.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$476.00</td>
<td>$442.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$472.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$380.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$395.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$357.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$450.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ulta Beauty. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ulta Beauty's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Ulta Beauty's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ulta Beauty analyst ratings.</a>
<h2>All You Need to Know About Ulta Beauty</h2>
With more than 1,400 freestanding stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. The firm intends to open franchises in Mexico in 2025. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
<h3>Unraveling the Financial Story of Ulta Beauty</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Ulta Beauty's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 1.65%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Ulta Beauty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ulta Beauty's ROE stands out, surpassing industry averages. With an impressive ROE of 10.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Ulta Beauty's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.92, Ulta Beauty adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ULTA

What Analysts Are Saying About Ulta Beauty Stock

On Thursday, the Dutch government inked a <a target="_blank" href="https://www.benzinga.com/topic/semiconductors" rel="noreferrer noopener">hardware and technological</a> expertise deal with Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) over a potential artificial intelligence (AI) facility.
The Netherlands targets a facility for an AI &#8216;supercomputer&#8217; that could potentially contribute to research and development.
In 2024, the Dutch government&nbsp;earmarked&nbsp;204.5 million euros ($210 million) for investments in AI.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/01/42843417/nvidia-highlights-ai-chips-powering-pubg-robotics-chatgpt-moment-automotive-expansion-and-more-at-ces-event" rel="noreferrer noopener">Nvidia Highlights AI Chips Powering PUBG, Robotics &#8216;ChatGPT Moment,&#8217; Automotive Expansion And More At CES Event</a>
The Nvidia deal coincided with reports indicating the Biden administration eying <a target="_blank" href="https://www.benzinga.com/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report" rel="noreferrer noopener">additional semiconductor sanctions</a> on allies and non-allies before passing the torch to the Trump administration on January 20.
Washington could impose three tiers of chip curbs, Bloomberg reported, citing unnamed sources familiar with the matter.
ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) of the Netherlands emerged as a key AI beneficiary, backed by its lithography portfolio and scalable EUV (Extreme Ultraviolet) technology, which helped contract chipmakers like Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) manufacture high-performance chips for Nvidia&#8217;s AI processors. 
The semiconductor equipment maker projected <a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">annual sales of</a> $46.51 billion – $63.43 billion (44 billion euros – 60 billion euros) by 2030 and a gross margin target of 56%-60%. It expects global sales to surpass $1 trillion by 2030, backed by the integration of AI across industries.
Price Action:&nbsp;NVDA stock closed lower by 0.02% at $140.11 Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42882959/intel-partners-with-amazon-cloud-to-drive-next-gen-smart-vehicle-tech" target="_blank" rel="noreferrer noopener">Intel Partners with Amazon Cloud to Drive Next-Gen Smart Vehicle Tech, Wins Stellantis, Karma Auto As Clients</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Eurozone

Tech

Media

ASML

NVDA

Nvidia Teams Up with Dutch Government to Build Cutting-Edge AI Supercomputer Facility

Stifel analyst David Grossman downgrades Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) from Buy to Hold and lowers the price target from $8 to $7.03.

Downgrades

Price Target

ACCD

Stifel Downgrades Accolade to Hold, Lowers Price Target to $7.03

Goldman Sachs analyst Will Nance upgrades BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) from Neutral to Buy and raises the price target from $96 to $104.

Upgrades

BILL

Goldman Sachs Upgrades BILL Holdings to Buy, Raises Price Target to $104

Goldman Sachs analyst Will Nance downgrades Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) from Buy to Neutral and lowers the price target from $155 to $122.

Goldman Sachs Downgrades Global Payments to Neutral, Lowers Price Target to $122

B of A Securities analyst Ken Hoexter maintains Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) with a Underperform and raises the price target from $60 to $62.

B of A Securities Maintains Underperform on Greenbrier Companies, Raises Price Target to $62

On Wednesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) said it has temporarily paused all U.S. cases using its Varipulse pulsed field ablation (PFA) system.
Pulsed-field ablation (PFA) is&nbsp;a non-thermal procedure that uses high-amplitude electrical pulses to treat cardiac arrhythmias (irregular heartbeat) and tumors.
In November, the FDA <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-receives-fda-approval-for-the-varipulse-pulsed-field-ablation-platform-for-the-treatment-of-atrial-fibrillation" rel="noreferrer noopener">approved</a> the Varipulse Platform for drug-refractory paroxysmal Atrial Fibrillation (AFib).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
The VARIPULSE Platform is designed to enable AFib treatment with a single device that combines PFA therapy and advanced mapping with the CARTO 3 System, a 3D electroanatomical cardiac mapping system.
"On January 5, out of an abundance of caution, Johnson &amp; Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation," the company <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-varipulse-u-s-external-evaluation" rel="noreferrer noopener">said</a>.
Neurovascular events are&nbsp;a range of conditions that affect the blood vessels and blood supply to the brain, spinal cord, and peripheral nerves.
Since the beginning of the external evaluation, the company has reported more than 130 cases of Varipulse in the U.S., spread across 14 sites and 40 operators. Globally, it has reported more than 3,000 commercial cases with Varipulse.
"We are working diligently to complete the investigation according to our medical safety processes and resume the U.S. External Evaluation," the company said in its statement. "We expect to have more information to communicate within the coming days."
Last month, the FDA issued a complete response letter (CRL) to&nbsp;Johnson &amp; Johnson's Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration in patients with non-small cell lung cancer with epidermal growth <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42535810/fda-rejects-johnson-johnsons-injectable-version-of-approved-drug-for-lung-cancer" rel="noreferrer noopener">factor receptor mutations</a>.
The CRL is&nbsp;related&nbsp;to observations as part of a standard pre-approval inspection at a manufacturing facility.
Price Action: JNJ stock closed at $146.23 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42897109/british-retail-giant-marks-spencer-warns-of-economic-challenges-despite-strong-sales-growth-in-food-and-retail" target="_blank" rel="noreferrer noopener">British Retail Giant Marks &amp; Spencer Warns Of Economic Challenges Despite Strong Sales Growth In Food And Retail</a></li>
</ul>
Photo by Tada Images via Shutterstock

Health Care

Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events

B of A Securities analyst Jason Gerberry reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

Reiteration

CPRX

B of A Securities Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) announced on Thursday the commencement of shipments for its max-performance servers featuring<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42896497/supermicro-begins-volume-shipments-of-max-performance-servers-optimized-for-ai-hpc-virtualization-" rel="noreferrer noopener"> Intel Xeon 6900 series processors with P-cores.</a>
These systems are optimized for demanding high-performance workloads such as large-scale AI, cluster-scale HPC, and GPU-intensive environments like collaborative design and media distribution, the company said in a press release.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SMCI stock has lost over 5% in the past year.
Supermicro&#8217;s new X14 systems offers up to 256 performance cores per system, 12 memory channels per CPU with MRDIMM support, and high-performance EDSFF storage options.
The systems are designed for low latency and maximum I/O expansion, making them ideal for large-scale applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42898200/targets-wellness-push-over-50-of-new-items-priced-under-10" rel="noreferrer noopener">Target&#8217;s Wellness Push: Over 50% Of New Items Priced Under $10</a>
Charles Liang, President and CEO, emphasized the company&#8217;s ability to ship solutions at any scale, supported by its Server Building Block Solutions design methodology and in-house liquid cooling solutions.
The X14 systems come in various configurations, including GPU-optimized models supporting the latest SXM and PCIe GPUs, high-density multi-node systems such as FlexTwin and GrandTwin models, and market-proven SuperBlade rackmounts for enterprises and data centers.
They also include options for direct-to-chip liquid cooling, significantly enhancing system efficiency and reducing thermal throttling.
Supermicro said it is now shipping AI server based on the Intel Gaudi 3 accelerator hosted by Intel Xeon 6 processors.
Investors can gain exposure to the stock via&nbsp;Defiance Daily Target 2X Long SMCI ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCX#NASDAQ">SMCX</a>).
Price Action: SMCI shares closed at $32.61 on Wednesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42890191/trump-themed-nfts-launch-on-bitcoin-network-for-first-timeheres-what-you-should-know" target="_blank" rel="noreferrer noopener">Trump-Themed NFTs Debut On Bitcoin Network — One Card Gets Listed At $1.9 Million</a></li>
</ul>

SMCI

SMCX

Super Micro Begins Shipping Max-Performance Servers With Intel Xeon 6900 Series Processors

Concentrix Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NYSE">CNXC</a>) will release its fourth-quarter financial results after the<a href="https://www.benzinga.com/quote/CNXC/earnings"> closing bell on Wednesday, Jan. 15.</a>
Analysts expect the Newark, California-based company to report quarterly earnings at $3.01 per share, down from $3.36 per share in the year-ago period. Concentrix projects quarterly revenue of $2.44 billion, compared to $2.23 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 25, Concentrix reported quarterly earnings of $2.87 per share, which missed the analyst consensus estimate of $2.93 per share.
Concentrix shares fell 0.4% to close at $45.60 on Wednesday&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Baird analyst David Koning initiated coverage on the stock with an Outperform rating and a price target of $70 on Oct. 3, 2024. This analyst has an accuracy rate of 79%.</li>
<li>Barrington Research analyst Vincent Colicchio maintained an Outperform rating and cut the price target from $84 to $70 on Sept. 26, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Canaccord Genuity analyst Joseph Vafi maintained a Buy rating and cut the price target from $125 to $100 on Sept. 26, 2024. This analyst has an accuracy rate of 80%.</li>
</ul>
Considering buying CNXC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09123810/image-53-1024x594.png" alt="" class="wp-image-726577" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09123810/image-53-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09123810/image-53-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09123810/image-53-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09123810/image-53.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower (UPDATED)</a></li>
</ul>

Earnings

Trading Ideas

CNXC

Top Wall Street Forecasters Revamp Concentrix Price Expectations Ahead Of Q4 Earnings

Curevac N.V. ( ($CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac N.V....

CureVac Reports Significant Revenue Growth Amid Strategic Restructuring

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company's shares closed yes...

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00. Roy Bucha...

CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating

California Gov. Newsom declares State of Emergency over bird flu

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Bird flu claims first U.S. life in Louisiana

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after t...

Comments

CureVac

ニュース

最新ニュース CureVac (NASDAQ:CVAC) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル